ADAG
Adagene, Inc.
NASDAQ · Healthcare · Biotechnology · CN
$2.46
+4.68%Oct 28, 2026, 11:00 UTC
Adagene announced that the first patient was dosed in a Phase 1 study evaluating muzastotug in combination with INCYTE CORP's INCA33890 in third-line microsatellite-stable colorectal cancer patients, with and without liver metastases.
Source:Sep 22, 2026, 12:00 UTC
China's National Medical Products Administration approved Adagene's investigational new drug application for ADG138, a double-masked HER2xCD3 bispecific T-cell engager, with a Phase 1 study in advanced solid tumors expected to begin in China in Q4 2026.
Source:Sep 10, 2026, 12:00 UTC
Third Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene for the development of masked CD3 T cell engagers utilizing Adagene's SAFEbody technology.
Source: